Anti-CD147 chimeric antigen receptor-natural killer Cell Therapy - Protheragen
Alternative Names: CD147-CAR-NKLatest Information Update: 11 Oct 2021
At a glance
- Originator Protheragen
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Liver cancer
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 11 Oct 2021 Anti-CD147 chimeric antigen receptor-natural killer Cell Therapy - Protheragen is available for licensing as of 11 Oct 2021. https://www.protheragen.com/available-projects/off-the-shelf-anti-cd147-car-nk-cell-therapy-for-hepatocellular-carcinoma/
- 11 Oct 2021 Protheragen announces intention to submit IND to for Liver cancer (Protheragen pipeline, October 2021)
- 07 Oct 2021 Preclinical trials in Liver cancer in USA (Parenteral) before October 2021 (Protheragen's pipeline, October 2021)